Technical Data
B2553-32
Bone Morphogenetic Protein 7 (BMP7, OP-1, Osteogenic Protein-1) Human, Recombinant
2ug
10ug
Molecular Biology Storage: -20CShipping: RT
BMP-7 (osteogenic protein 1) belongs to the Bone-growth regulatory factors that are members of the transforming growth factor-beta (TGF-beta) superfamily of proteins. They are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins.

Recombinant Human BMP-7 is a monomeric, non-glycosylated, Polypeptide chain containing 139 amino acids and having a molecular mass of 15.68kD.

Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Thr-Gly-Ser-Lys.

Applications:
Suitable for use in Western Blot, ELISA, preparing antibodies for BMP-7 monomer and as a molecule standard in detecting secreted BMP-7 in reduced SDS-PAGE. Other applications not tested.

Storage and Stability:
Lyophilized powder may be stored at -20C. Reconstitute with sterile 20mM acetic acid. Aliquot and store at -20C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer with 0.1% HSA or BSA.

Molecular Weight:
15.68kD
Source: Recombinant, Human (E. coli).
Purity: 95% by RP-HPLC or SDS-PAGE. Chromatographically purified.Chromatographically purified.
Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder in 10mM sodium citrate, pH 3.5. Reconstitute with sterile 20mM acetic acid to 0.1mg/ml. This solution can then be diluted into other aqueous solutions with 0.1% HSA or BSA.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Sinus floor augmentation with simultaneous placement of dental implants in the presence of platelet-rich plasma or recombinant human bone morphogenetic protein-7. Roldan JC, Jepsen S, Knuppel H, Clin Oral Implants Res 2004 Dec;15(6):716-23 2. Histological assessment of bioengineered new bone in repairing osteoperiosteal mandibular defects in sheep using recombinant human bone morphogenetic protein-7. Abu-Serriah MM, Odell E, Gillar A, Br J Oral Maxillofac Surg 2004 Oct;42(5):410-8 3. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Li T, Surendran K, Mathew S, Curr Opin Nephrol Hypertens 2004 Jul;13(4):417-22 4. Bone morphogenetic protein-7 from serum of pregnant mice is available to the fetus through placental transfer during early stages of development. Borovecki F, Jelic M, Sampath KT, Nephron Exp Nephrol 2004;97(1):e26-32 5. Are recombinant human bone morphogenetic protein-7 and tobramycin compatible? An experiment in rats. Kawaguchi AT, Reddi AH, Yinger KE, J Orthop Trauma 2004 Apr;18(4):225-32 6. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. Wang S, Hirschberg R, J Biol Chem 2004 May 28;279(22):23200-6

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.